Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003078695 | SCV003476059 | uncertain significance | 3-hydroxy-3-methylglutaryl-CoA synthase deficiency | 2022-01-11 | criteria provided, single submitter | clinical testing | This sequence change replaces alanine, which is neutral and non-polar, with glycine, which is neutral and non-polar, at codon 284 of the HMGCS2 protein (p.Ala284Gly). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. This variant has not been reported in the literature in individuals affected with HMGCS2-related conditions. This variant is present in population databases (rs201182715, gnomAD 0.002%). |
Ambry Genetics | RCV003161759 | SCV003889917 | uncertain significance | Inborn genetic diseases | 2023-03-02 | criteria provided, single submitter | clinical testing | The c.851C>G (p.A284G) alteration is located in exon 5 (coding exon 5) of the HMGCS2 gene. This alteration results from a C to G substitution at nucleotide position 851, causing the alanine (A) at amino acid position 284 to be replaced by a glycine (G). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |